Literature DB >> 32970500

Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma.

Michael Asger Andersen1,2, Rebecca Valentin1,3, Lene Dissing Sjö4, Line Borgwardt5, Kjeld Schmiegelow6,7, Mette Klarskov Andersen4,8, Rasmus L Marvig5, Christina Westmose Yde5, Carsten Utoft Niemann1.   

Abstract

Entities:  

Year:  2020        PMID: 32970500     DOI: 10.1080/0284186X.2020.1821913

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  1 in total

1.  Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia.

Authors:  Paul J Hampel; Sameer A Parikh; Timothy G Call; Mithun V Shah; N Nora Bennani; Aref Al-Kali; Kari G Rabe; Yucai Wang; Eli Muchtar; Jose F Leis; Saad S Kenderian; Amber B Koehler; Susan M Schwager; Susan L Slager; Neil E Kay; Curtis A Hanson; Daniel L Van Dyke; Min Shi; Wei Ding
Journal:  Blood Cancer J       Date:  2021-03-02       Impact factor: 11.037

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.